CompanyOverview|NYSE:HIMS] One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of branded versions of Eli Lilly’s (NYSE:LLY) popular weight loss therapy ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

Studies have found that patients lose around 21% of their weight on average at the highest dose. This is significantly more than the 15% seen by Novo Nordisk's A/S (NYSE: NVO) Wegovy. Hims will ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like Ozempic and Mounjaro. That gamble has now collapsed.

Studies have found that patients lose around 21% of their weight on average at the highest dose. This is significantly more than the 15% seen by Novo Nordisk's A/S NVO Wegovy. Hims will also offer ...